In a systematic review using 5 comparator studies, treatment of multidrug-resistant (MDR) latent TB infection did suggest effectiveness in the prevention of progression to MDR-TB disease among contacts of a person with MDR-TB disease.52 However, an observational study found a lower rate of progression to TB disease among MDR contacts taking 12 months of a fluoroquinolone with or without ethambutol or ethionamide, compared to those refusing treatment.53 Trials to assess levofloxacin as a TPT for MDR-TB contacts are ongoing to determine if this approach is indeed effective.54,55 At present, there is insufficient evidence to make a recommendation regarding TPT for contacts of fluoroquinolone-resistant MDR cases. However, a trial of delamanid for high-risk MDR-TB contacts is ongoing and may inform future recommendations.56
Recommendation
-
We conditionally recommend, for contacts of an index TB patient who is known to have an isolate resistant to both rifampin and isoniazid (MDR-TB), levofloxacin or moxifloxacin for six-to-nine months if the source case is fluoroquinolone-sensitive (poor evidence).
Good practice statements
-
For contacts of an index TB patient who is known to have an isoniazid mono-resistant isolate, we suggest 4 months of daily rifampin (4R).
-
For contacts of an index TB patient who is known to have a rifampin mono-resistant isolate, we suggest 9 months of isoniazid (9H).
-
All patients with latent tuberculosis infection who are contacts of a person with MDR-TB should be followed for 2 years to ensure that they do not develop disease.
Switch To: Français